| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 05/17/2011 | CA2353553C Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia |
| 05/12/2011 | WO2011057251A2 Treatment of heart disease |
| 05/12/2011 | WO2011057249A2 Treatment of heart disease |
| 05/12/2011 | WO2011057243A2 Administration of plant expressed oral tolerance agents |
| 05/12/2011 | WO2011057027A2 Method for treating heart failure with stresscopin-like peptides |
| 05/12/2011 | WO2011056511A2 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase |
| 05/12/2011 | WO2011056477A2 Methods for treating inflammation and oxidative stress related diseases |
| 05/12/2011 | WO2011056416A2 Cardiomyocyte production |
| 05/12/2011 | WO2011056234A1 Treatment for radiation-induced disorders |
| 05/12/2011 | WO2011056126A1 Novel 1,3-oxazolidine compounds and their use as renin inhibitors |
| 05/12/2011 | WO2011056037A2 Pharmaceutical composition containing, as active ingredients, lindera erythrocarpa extracts, fractions thereof, or compounds separated from the extracts |
| 05/12/2011 | WO2011055561A1 Protein crosslinking inhibitor and use thereof |
| 05/12/2011 | WO2011055550A1 Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent |
| 05/12/2011 | WO2011054916A1 Methods and pharmaceutical composition for the treatment of atherosclerosis |
| 05/12/2011 | WO2011054699A1 Use of biocompatible compositions and materials polymerized therefrom for inhibiting angiogenesis |
| 05/12/2011 | WO2011054301A1 Use of danshensu, notoginsenoside r1 or their combination in preparation of medicaments for preventing and treating diseases caused by microcirculation disorder |
| 05/12/2011 | WO2011054182A1 Sodium transhinone iia sulfonate hydrate and preparation method and use thereof |
| 05/12/2011 | WO2011034509A3 New benzathine salts of ace inhibitors, process for their preparation and their use for the treatment of cardiovascular diseases |
| 05/12/2011 | WO2010138555A3 Small peptide expression system in mammalian cells |
| 05/12/2011 | US20110112280 Use of rgm and its modulators |
| 05/12/2011 | US20110112186 Diagnostic methods |
| 05/12/2011 | US20110112177 Human G-Protein Coupled Receptor (HETGQ23) |
| 05/12/2011 | US20110112171 Compositions and their uses directed to ptpru |
| 05/12/2011 | US20110112168 Novel sirna structures |
| 05/12/2011 | US20110112165 Atorvastatin-aliskiren |
| 05/12/2011 | US20110112162 Spiro-oxindole compounds and their use as therapeutic agents |
| 05/12/2011 | US20110112160 Tablet comprising eprosartan mesylate |
| 05/12/2011 | US20110112156 Bicyclic Derivatives as Modulators of Voltage Gated ION Channels |
| 05/12/2011 | US20110112154 Compounds, compositions and methods |
| 05/12/2011 | US20110112151 Compound capable of inhibiting 11-beta hydroxysteriod dehydrogenase |
| 05/12/2011 | US20110112149 Epothilone analogues, their pharmaceutical compositions, their use and their prepa rations |
| 05/12/2011 | US20110112146 Chromene modulators of chemokine receptor activity |
| 05/12/2011 | US20110112145 Salts Of Methyl 2-((R))-(3-Chlorophenyl)((R)-1-((S)-2-(Methylamino)-3((R)-tetrahydro-2H-Pyran-3-YL)Propylcarbamoyl)Piperidin-3-YL)Methoxy)Ethylcarbamate |
| 05/12/2011 | US20110112142 Novel estrogen receptor ligands |
| 05/12/2011 | US20110112140 Inhibitor of plasminogen activator inhibitor-1 |
| 05/12/2011 | US20110112134 Tricyclic Antagonists of Prostaglandin D2 Receptors |
| 05/12/2011 | US20110112132 Means for the treatment of acute and chronic disorders of cerebral circulation, including insult, based on hydrogenated pyrido (4,3-b) indoles (variants), pharmacological means based thereon and method for the use thereof |
| 05/12/2011 | US20110112126 Enzyme inhibiting compounds |
| 05/12/2011 | US20110112120 Heteromonocyclic compound and use thereof |
| 05/12/2011 | US20110112119 Azabicyclooctyl-quinazolone derivatives useful as nicotinic acetylcholine receptor modulators |
| 05/12/2011 | US20110112113 Methods of predicting and treating adverse cardiac events |
| 05/12/2011 | US20110112111 Drug combinations comprising a dgat inhibitor and a ppar-agonist |
| 05/12/2011 | US20110112094 Methods of Treating Pulmonary Hypertension |
| 05/12/2011 | US20110112092 Aminoquinoline derivatives and their use as adenosine a3 ligands |
| 05/12/2011 | US20110112090 Depsipeptides and Their Therapeutic Use |
| 05/12/2011 | US20110112083 Fxa inhibitors with cyclic amidoxime or cyclic amidrazone as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof |
| 05/12/2011 | US20110112082 Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| 05/12/2011 | US20110112080 Oxazoline derivatives |
| 05/12/2011 | US20110112078 Novel oxadiazolyl-diazabicyclononane derivatives and their medical use |
| 05/12/2011 | US20110112076 Selective hydroxamic acid based mmp-12 and mmp-13 inhibitors |
| 05/12/2011 | US20110112075 Chlorothiophene-amides as inhibitors of coagulation factors xa and thrombin |
| 05/12/2011 | US20110112074 Chlorothiophene-isoxazoles as inhibitors of coagulation factors xa and thrombin |
| 05/12/2011 | US20110112073 Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof |
| 05/12/2011 | US20110112067 Inhibitors of the Human Aldosterone Sythase CYP11B2 |
| 05/12/2011 | US20110112066 Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof |
| 05/12/2011 | US20110112058 Novel modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| 05/12/2011 | US20110112053 Pharmacological targeting of vascular malformations |
| 05/12/2011 | US20110112037 Crystal structure |
| 05/12/2011 | US20110112032 Regulation of Brain Natriuretic Peptide and Catecholamines for the Treatment of Cardiovascular Diseases |
| 05/12/2011 | US20110112030 Methods of treating or preventing stent thrombosis |
| 05/12/2011 | US20110112016 Compositions and methods for modulating the immune system |
| 05/12/2011 | US20110111528 Modified polypeptides stabilized in a desired conformation and methods for producing same |
| 05/12/2011 | US20110111493 Compositions and Methods For Inhibiting Expression Of A Target Gene |
| 05/12/2011 | US20110111059 Compositions Comprising Quinazoline Derivatives, Preparation Methods and Uses Thereof |
| 05/12/2011 | US20110111058 Methods for increasing the stabilization of hypoxia inducible factor-1 alpha |
| 05/12/2011 | US20110111054 Bmp-7 for use in treating vascular sclerosis |
| 05/12/2011 | US20110111049 Ischemia/reperfusion protection compositions and methods of using |
| 05/12/2011 | US20110111042 Self-microemulsifying systems incorporated into liquid core microcapsules |
| 05/12/2011 | US20110111029 Composition for transdermal delivery of cationic active agents |
| 05/12/2011 | US20110111026 Humidity-resistant drug formulations and methods of preparation thereof |
| 05/12/2011 | US20110111024 Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use |
| 05/12/2011 | US20110111022 Pharmaceutical formulation |
| 05/12/2011 | US20110110950 Therapeutic regimens for BAFF antagonists |
| 05/12/2011 | US20110110930 Mitogen-Activated Protein Kinase Kinase Kinase 14 (MAP3K14) Polymorphisms As Indicators of Subject Outcome in Critically Ill Subjects |
| 05/12/2011 | US20110110924 Resistin as a Marker and Therapeutic Target for Cardiovascular Disease |
| 05/12/2011 | US20110110920 Method of treating peripheral arterial disease |
| 05/12/2011 | US20110110917 Human Aminoacyl-tRNA Synthetase Polypeptides Useful For The Regulation of Angiogenesis |
| 05/12/2011 | US20110110916 Methods for treating and/or preventing cardiomyopathies by erk or jnk inhibition |
| 05/12/2011 | US20110110908 Treatment of disease conditions via administration of dna repair enzyme |
| 05/12/2011 | US20110110903 Cell fusion promoter and utilization of the same |
| 05/12/2011 | US20110110902 Means and methods for counteracting, delaying and/or preventing heart disease |
| 05/12/2011 | US20110110899 Combined Chemical and Genetic Approaches for Generation of Induced Pluripotent Stem Cells |
| 05/12/2011 | US20110110897 Adult Human Cardiac-Derived Progenitor Cells |
| 05/12/2011 | US20110110893 Therapeutic agent for anaerobic diseases |
| 05/12/2011 | US20110110885 Bioactive Depside and Anthocyanin Compounds, Compositions, and Methods of Use |
| 05/12/2011 | US20110110868 Functionalized Magnetic Nanoparticles and Methods of Use Thereof |
| 05/12/2011 | US20110110866 Elastin-like polypeptide and gadolinium conjugate for magnetic resonance imaging |
| 05/12/2011 | US20110110860 Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter |
| 05/12/2011 | US20110110855 Novel ghrelin analogues |
| 05/12/2011 | US20110110854 Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules |
| 05/12/2011 | US20110110853 Primitive vascular progenitor cells and uses thereof |
| 05/12/2011 | CA2781322A1 Use of danshensu, notoginsenoside r1 or their combination in preparation of medicaments for preventing and treating diseases caused by microcirculation disorder |
| 05/12/2011 | CA2780362A1 Administration of plant expressed oral tolerance agents |
| 05/12/2011 | CA2780163A1 Method for treating heart failure with stresscopin-like peptides |
| 05/12/2011 | CA2779989A1 Quinazoline compounds |
| 05/12/2011 | CA2777552A1 Cardiomyocyte production |
| 05/12/2011 | CA2777455A1 Novel 1,3-oxazolidine compounds and their use as renin inhibitors |
| 05/11/2011 | EP2319870A2 Human antibodies that bind human IL-12 and methods for producing |
| 05/11/2011 | EP2319868A1 Immunotherapeutic treatment for inducing the regression of atherosclerotic plaques |
| 05/11/2011 | EP2319847A2 Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP |